S. Ammoun,L. Zhou,M. Barczyk,D. Hilton,S. Hafizi,C. Hanemann,K. S. Lehnus,L. K. Donovan,G. J. Pilkington,Q. An,I. A. Anderson,S. Thomson,M. Bailey,E. Lekka,J. Law,C. Davis,K. Banfill,C. Loughrey,P. Hatfield,D. Bax,R. Elliott,R. Bishop,K. Taylor,L. Marshall,N. Gaspar,M. Viana-Pereira,R. Reis,J. Renshaw,A. Ashworth,C. Lord,C. Jones,C. Bellamy,L. Shaw,J. Alder,A. Shorrocks,R. Lea,S. Birks,M. Burnet,G. Pilkington,J. D. Bruch,J. Ho,C. Watts,S. J. Price,S. Camp,V. Apostolopoulos,A. Mehta,F. Roncaroli,D. Nandi,B. Clark,M. Mackinnon,N. MacLeod,W. Stewart,A. Chalmers,A. Cole,G. Hanna,K. Bailie,D. Conkey,J. Harney,C. Darlow,S. Chapman,L. Mohsen,S. Price,L. Donovan,H. Dyer,H. Lord,K. Fletcher,R. das Nair,J. MacNiven,S. Basu,P. Byrne,L. Glancz,G. Critchley,M. Grech-Sollars,D. Saunders,K. Phipps,J. Clayden,C. Clark,A. Greco,S. Acquati,S. Marino,S. Hammouche,S. P. Wilkins,T. Smith,A. Brodbelt,S. Clark,A. H. L. Wong,P. Eldridge,J. O. Farah,J. Bruch,G. Lamb,S. Smith,A. James,M. Glegg,T. Jeffcote,S. Boulos,P. Robbins,N. Knuckey,A. Banigo,A. R. Brodbelt,M. D. Jenkinson,J. N. Jeyapalan,M. A. Mumin,T. Forshew,A. R. Lawson,R. G. Tatevossian,T. S. Jacques,D. Sheer,J. Kilday,K. Wright,S. Leavy,J. Lowe,E. Schwalbe,S. Clifford,R. Gilbertson,B. Coyle,R. Grundy,P. Kinsella,M. Clynes,V. Amberger-Murphy,N. Barron,S. R. Lambert,D. Jones,D. Pearson,I. Ichimura,V. Collins,L. Steele,P. Sinha,P. Chumas,J. Tyler,D. Ogawa,E. Chiocca,M. DeLay,A. Bronisz,M. Nowicki,J. Godlewski,S. Lawler,M. K. Lee,M. Javadpour,P. Abel,T. Dawson,B. Lea,C. S.-K. Lim,P. L. Grundy,M. Pendleton,A. Williamson,A. Merve,X. Zhang,S. Miller,H. A. Rogers,P. Lyon,V. Rand,M. Adamowicz-Brice,S. C. Clifford,J. T. Hayden,S. Dyer,S. Pfister,A. Korshunov,M.-A. Brundler,R. G. Grundy,M. Nankivell,P. Mulvenna,R. Barton,P. Wilson,C. Faivre-Finn,C. Pugh,R. Langley,D. Ngoga,D. Tennant,A. Williams,P. Moss,G. Cruickshank,K. Owusu-Agyemang,S. Bell,J. St.George,S. G. Piccirillo,S. Qadri,E. Pirola,M. Jenkinson,R. Rahman,C. Rahman,D. MacArthur,F. Rose,K. Shakesheff,C. Carroll,P. Watson,M. Hawkins,H. Spoudeas,D. Walker,T. Holland,H. Ring,A. Rooney,S. McNamara,M. Fraser,R. Rampling,A. Carson,R. Grant,J. Royds,S. Al Nadaf,A. Ahn,Y.-J. Chen,A. Wiles,D. Jellinek,A. Braithwaite,B. Baguley,M. MacFarlane,N. Hung,T. Slatter,S. Rusbridge,N. Walmsley,S. Griffiths,P. Wilford,J. Rees,D. Ryan,P. Liu,S. Galavotti,M. Shaked-Rabi,E. Tulchinsky,S. Brandner,P. Salomoni,A. Schulte,H. S. Gunther,S. Zapf,S. Riethdorf,M. Westphal,K. Lamszus,S. K. Selvanathan,H. J. Salminen,S. Setua,M. E. Welland,M. Shevtsov,W. Khachatryan,A. Kim,K. Samochernych,A. Pozdnyakov,I. V. Guzhova,I. V. Romanova,B. Margulis,J. Barrow,D. Macarthur,A. Long,Z. Maherally,J. R. Smith,L. Dickson,S. Prabhu,F. Harris,T. J. Snape,M. Sussman,S. Wilne,W. Whitehouse,G. Chow,J.-F. Liu,T. Snape,A. Karakoula,F. Rowther,T. Warr,A. Zisakis,V. Varsos,A. Panteli,O. Karypidou,A. Zampethanis,A. Fotovati,S. Abu-Ali,P.-S. Wang,L. Deleyrolle,C. Lee,J. Triscott,J. Y. Chen,S. Franciosi,Y. Nakamura,Y. Sugita,T. Uchiumi,M. Kuwano,B. R. Leavitt,S. K. Singh,A. Jury,H. Wakimoto,B. A. Reynolds,C. J. Pallen,S. E. Dunn,S. Shepherd,S. Scott,D. Bowyer,L. Wallace,B. Hacking,R. Jena,J. Gillard,M. Verraeult,B. Reynolds,C. Dunham,M. Bally,J. Hukin,S. Singhal,S. Singh,S. Dunn

Abstract:INTRODUCTION: Substituted indoles and related structures have been shown to exhibit potent anticancer activity against breast cancer cell lines. Here, the effects of structurally similar substituted indoles against the human glial cancer cell lines, 1321N1 and U87MG, have been investigated by comparing the effects of these compounds to conventional anti cancer drugs. METHODS: Cell viability in the presence of the test compounds was measured using an MTS assay and corroborated by an ATP cell proliferation assay as well as a Trypan blue exclusion test. The significance of reactive oxygen species (ROS) in the process was determined using an Image-iT® LIVE ROS kit from Invitrogen. RESULTS: Both cell lines were treated with four commercial anticancer drugs and IC50 values were only reached at concentrations of 20 µM for cisplatin and 50 µM for gemcitabine over 48hrs on the 1321N1 cell line. However, the more malignant U87MG cell line was resistant to all the drugs, except for cisplatin where the IC50 value was reached at 300 µM after treatment for 48hrs. Similar studies were carried out with various substituted indoles and the cytotoxicity results on both cell lines showed that the IC50 value was reached within 90 minutes for the most potent compound at a concentration of 600 µM (1321N1) and 800 µM (U87MG). The idea that the mechanism of action of these compounds may work through the generation of ROS was investigated and this was confirmed over a similar time course using a suitable fluorogenic marker. Moreover, it was shown that the addition of an antioxidant (ascorbic acid) abolished the potency of the most active compound. CONCLUSION: Here, it has been demonstrated that certain substituted indoles are able to have a rapid, deleterious effect on the viability of two glioma cell lines and indicated that ROS generation may induce cell death.

Supplemental Figures W/ Legends from Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Physalis Alkekengi Var. Franchetii Extracts Exert Antitumor Effects on Non-Small Cell Lung Cancer and Multiple Myeloma by Inhibiting STAT3 Signaling

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Prodelphinidins Isolated from Chinese Bayberry Leaves Induces Apoptosis Via the P53-Dependent Signaling Pathways in OVCAR-3 Human Ovarian Cancer Cells

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Alkaloids from Oxytropis Ochrocephala and Antiproliferative Activity of Sophoridine Derivatives Against Cancer Cell Lines.

Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figures 1-4 from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Materials and Methods from An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis

Supplementary Figure Legends 1-4 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplemental Figure Legends from Obesity Contributes to Ovarian Cancer Metastatic Success Through Increased Lipogenesis, Enhanced Vascularity, and Decreased Infiltration of M1 Macrophages

Supplementary Figures 1-3 from Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin Via Reactive Oxygen Species Modulation

Abstracts from the 2011 BNOS Conference, June 29 - July 1, 2011, Homerton College, Cambridge

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figures 6-8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment